| |
DOG Congress Home
Program Changes
Registration
Invitations
Organization, Deadlines
Overview of the Congress
Scientific Programme
Scientific Programme
Highlights
Symposia
Courses
Satellite Programme
Information
Social Programme
Sponsors, Exhibitors
For the Press
DOG Homepage
|
|
AbstractDO.01.06 One year results of intravitreal Bevacizumab for the treatment of macular edema secondary to branch retinal vein occlusion Kreutzer T. C.1, Alge C. S.1, Dirisamer M.1, Burger J.2, Haritoglou C.1, Kampik A.1, Priglinger S. G.2
1Augenklinik der LMU, München, Deutschland; 2Augenabteilung am AKH, Linz, Österreich Objective: To evaluate the effect of intravitreal bevacizumab (Avastin®) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion (BRVO).
Methods: A prospective, non comparative, consecutive, interventional case series of thirty-five patients. Patients received repeated intravitreal injections of 1.25mg bevacizumab. Main outcome measures were best corrected visual acuity (ETDRS chart) and optical coherence tomography measurements of central retinal thickness in a follow-up period of one year.
Results: Patients presented at a mean age of 69 years (range 44 86 years). Visual acuity at baseline was 0.78 LogMAR (±0.39) and improved to a mean of 0.54 LogMAR (±0.39) after six months (P = 0.003), 0.58 LogMAR (±0.41) after nine months (P = 0.018) and 0.47 LogMAR (±0.39) after 12 months (P = 0.002). Mean letter score on the ETDRS-chart at baseline was 45.5 (±19.0) and improved to a mean of 57.7 (±22.9) letters after six months (P < 0.001), 53.5 (±21.7) letters after nine months (P = 0.015) and 58.8 (±22.7) letters after twelve months (P = 0.002). Retinal thickness as measured by OCT at baseline was 472µm (±120) and declined to a mean of 330µm (±91) after six month (P = 0.001), 301µm (±100) after nine months (P < 0.001) and 286µm (±95) after 12 months (P = 0.001). Focal photolasercoagulation was performed in 18 of the 35 cases (51.4%). On average 3.0 (Range 1 8) intravitreal injections of 1.25mg bevacizumab were performed per eye.
Conclusions: Intravitreal injection of 1.25mg bevacizumab showed to be an effective treatment option for BRVO.
|
|
